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Enantiopure Fmoc-protected morpholine-3-carboxylic acid
was synthesized from dimethoxyacetaldehyde and serine
methyl ester through a short and practical synthetic route.
The preparation consisted of a five-step process based on
reductive amination, intramolecular acetalization, and con-
comitant elimination of the anomeric methoxy substituent,
followed by hydrogenation of the double bond and final
acidic ester hydrolysis. The optical purity of both enantiomers
of the title amino acid was demonstrated by HPLC analysis
of the corresponding amide derivatives obtained from
coupling with chiral (S)-(-)-1-phenylethylamine. Moreover,
the synthesis of a model tripeptide showed full compatibility
of the title Fmoc-amino acid with solid-phase peptide
synthesis, thus allowing the application of Fmoc-morpholine-
3-carboxylic acid in peptidomimetic chemistry on the solid
phase.
Over the years the synthesis and applications of cyclic amino
acids has attracted considerable attention from synthetic and
medicinal chemists, especially in the area of peptidomimetics.1
The incorporation of cyclic secondary amino acids2 has profound
effects on the conformation of peptides, due to the inability of
the nitrogen atom to act as a hydrogen bond donor unless it is
located at the N-terminal position of the molecule, and to the
conformational strain imparted by the cyclic structure. Also,
cis/trans isomerism of the tertiary amide bond formed by cyclic
amino acids is responsible for the modulation of the conforma-
tional preferences. Cyclic secondary amino acids have been ap-
plied in several biological issues, and their incorporation into
bioactive peptides has been reported over the years.3,4 In parti-
cular, morpholine-3-carboxylic acid has been used to synthesize
several bioactive molecules, such as TACE,5 MMP and TNF
inhibitors,6 and a potent orally active VLA-4 antagonist.7 Also,
it has been included in the core structure of tricyclic benzodiaze-
pines,8 6-methylidene penems as â-lactamase inhibitors,9 â-car-
bolines as IKK-2 inhibitors,10 8,6-fused bicyclic peptidomimetic
compounds as interleukin-1â converting enzyme inhibitors,11
and in the structure of benzoxazepines as stimulators of AMPA
receptor.12 The first syntheses of morpholine-3-carboxylic acid
were reported in 1981 by Anteunis et al. as a racemate,13 and
by Brown et al. describing the preparation of the cyclic amino
acid as the N-benzyl, ethyl ester derivative from serine in 6%
overall yield.14 In the same years, Kogami and Ogawa reported
the most convenient synthesis of morpholine-3-carboxylic acid,15
which employed chiral benzyl N-Cbz-2-aziridine-carboxylate,
derived from serine, to give the title amino acid after three steps
in 66% overall yield. Recently, Dave and Sasaki reported the
synthesis of enantiomerically pure Boc-morpholine-3-carboxylic
acid from the corresponding alcohol derivative in 81% yield,16
which in turn was obtained from a protected serinol derivative
in six steps and in 50% overall yield. In addition, an enzymatic
synthesis of cyclic amino acids, including morpholine-3-
carboxylic acid, has been proposed recently.17
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Given the importance of this amino acid in medicinal and
organic chemistry, we envisioned morpholine-3-carboxylic acid
coming from the condensation of serine methyl ester with
dimethoxyacetaldehyde to give the enantiomerically pure title
amino acid N-protected with the Fmoc group, which is of special
interest for solid-phase peptide and organic synthesis. Reductive
amination of dimethoxyacetaldehyde with L-serine methyl ester
hydrochloride was carried out under a hydrogen atmosphere in
the presence of catalytic amounts of 5% Pd/C, giving compound
3 in 50% yield. Optimization of the reaction conditions consisted
of the addition of 1 molar equiv of triethylamine, thus furnishing
clean adduct 3 in 98% yield after overnight stirring at room
temperature (Scheme 1).
Subsequent amine protection as Fmoc-urethane was achieved
by using Fmoc-Cl in water-dioxane as the solvent system, and
in the presence of NaHCO3 as base, giving 4 in 97% yield.
Acid-catalyzed cyclization by acetalization and in situ elimina-
tion of the methoxy group was achieved in one pot, by refluxing
compound 4 in toluene in the presence of catalytic quantities
of p-toluenesulfonic acid, thus giving 5 as a single stereoisomer
in 85% yield. When the reaction was carried out without using
molecular sieves, we observed a decrease of the yield to 67%,
and the reaction time was prolonged to 4 h to achieve complete
conversion of the starting material. Hydrogenation of the double
bond at C-5 and C-6 carbon atoms of 5 was initially attempted
by treatment with H2 and catalytic 10% Pd/C, leading to partial
deprotection of the amine function (Table 1). The extent of such
deprotection was found to be dependent on the choice of the
solvent, as when 2:1 MeOH-CH2Cl2 was used as the solvent
mixture the amount of deprotected amino ester increased,
compared to MeOH (Table 1, entries 1 and 2). The use of
Raney-Ni as catalyst was unsuccessful, as only starting material
was recovered from the reaction mixture.
Finally, 10% Pt/C catalyst gave clean reduction of the double
bond and allowed preservation of the amine protecting group.
The reaction proceeded in 91% with MeOH as solvent, and upon
application of 2:1 MeOH-CH2Cl2 as the solvent system, the
yield was further optimized to 95% (Table 1, entry 5).
Hydrolysis of the ester function to give the title Fmoc-protected
amino acid was carried out in an acidic medium to preserve
the base-labile Fmoc group. Optimization of the reaction
conditions required several attempts to achieve high yield.
Hydrolysis of 6 in 2:1 acetonitrile-4 M HCl with overnight
stirring at room temperature resulted in poor conversion, giving
7 in 15% yield. Replacement of acetonitrile with dioxane,
without altering the other reaction conditions, produced 7 in
29% yield. A marked improvement was obtained by raising the
reaction temperature. In fact, the hydrolysis was carried out by
refluxing the Fmoc-amino ester 6 in a 0.07 M 1:1 dioxane-4
M HCl solution for 2.5 h, giving 7 in 69% yield. Further
optimization gave 7 in 97% yield by overnight refluxing a 0.2
M solution of 6 in a 1:1 mixture of 5 M HCl-dioxane.
Consequently, compound (S)-7 was obtained in five steps and
an overall yield of 74%. Also, the synthesis of the corresponding
enantiomeric (R)-Fmoc-morpholine-3-carboxylic acid [(R)-7]
was carried out starting from D-serine methyl ester, giving the
title amino acid in 73% overall yield.
Enantiomeric purity of (R)-7 and (S)-7 was determined by
preparing and analyzing the corresponding diastereomeric
amides obtained by reaction with a chiral amine, followed by
HPLC analysis,18 according to methods reported for similar
compounds.19 Thus, coupling between (S)-(-)-1-phenylethy-
lamine (98% pure) and (S)-7 or (R)-7 was carried out with
HBTU/HOBt and DIPEA in CH2Cl2 at room temperature for 3
h, giving the corresponding diastereomeric amides in quantitative
yields. Since the 1:1 mixture of the two diastereoisomers could
not be separated by reverse-phase HPLC due to similar retention
times, we found it more convenient to deprotect a 1 mg/mL
analytical sample of each of the two diastereomeric amides in
acetonitrile with a drop of piperidine. The two deprotected
samples showed different retention times, and the enantiomeric
purity of the final product was measured by HPLC, giving a de
>96%, without any detectable traces of the parent isomer in
both cases (see the Supporting Information).
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SCHEME 1
TABLE 1. Optimization of Reaction Conditions for the Double
Bond Hydrogenation of 5
entry catalyst solvent yield, %
1 10% Pd/C MeOH 67a
2 10% Pd/C 2:1 MeOH-CH2Cl2 25a
3 Raney Ni MeOH b
4 10% Pt/C MeOH 91
5 10% Pt/C 2:1 MeOH-CH2Cl2 95
a Partial deprotection of the Fmoc group was observed b Only starting
material was recovered
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Also, Fmoc-3-morpholine carboxylic acid was applied in the
solid-phase synthesis of a model tripeptide with use of Rink-
HMBA resin and DIC/HOBt as the activating mixture. The
internal colorimetric Bromophenol Blue test, as reported by
Krchna´k et al.,20 was used to monitor the coupling efficiency
on both amino and carboxylic functions of morpholine-3-
carboxylic acid. Thus, Fmoc-Phe-morpholine-3S-CO-Leu-NH2
8 was synthesized. The coupling reactions proved to proceed
slower on both functions compared to those on acyclic R-amino
acids. The crude tripeptide was obtained in 90% yield after
cleavage from the resin, and in 86% purity as determined by
HPLC, thus showing full compatibility with solid-phase peptide
chemistry.
In summary, we have shown a convenient synthetic strategy
for the preparation of enantiomerically pure N-Fmoc-morpho-
line-3-carboxylic acid starting from cheap commercially avail-
able serine methyl ester hydrochloride and dimethoxyacetalde-
hyde, resulting in the preparation of both enantiomers on a gram
scale. Determination of enantiomeric purity by HPLC revealed
the proposed synthetic strategy proceeded with high stereocon-
servation, without any traces of racemization. Finally, the
synthesis of a model tripeptide by solid-phase techniques proved
the title amino acid to be compatible with the solid-phase peptide
synthesis, although showing lower reactivity compared to that
of proteinogenic acyclic R-amino acids, thus demonstrating the
application of the title amino acid in solid-phase protocols for
medicinal chemistry.
Experimental Section
(2S)-2-(2,2-Dimethoxyethylamino)-3-hydroxypropionic Acid
Methyl Ester (3). L-Serine methyl ester hydrochloride (1.00 g, 6.47
mmol) was dissolved in MeOH (20 mL), then triethylamine (902
íL, 6.47 mmol), a 60% aqueous solution of dimethoxyacetaldehyde
(1.11 g, 6.47 mmol), and 10% Pd/C (90 mg) were successively
added, and the resulting mixture was stirred overnight at room
temperature under a hydrogen atmosphere. Next, the suspension
was filtered on Celite and the organic solvent was removed under
reduced pressure. The crude product was purified by flash column
chromatography (CH2Cl2-MeOH 12:1, Rf 0.43) to yield 3 as a
colorless oil (1.31 g, 98%). [R]24D -28.5 (c 1.0, CH2Cl2). 1H NMR
(400 MHz, CDCl3) ä 4.44 (t, J ) 4.5 Hz, 1 H), 3.77 (dd, J ) 11.2,
4.5 Hz, 1 H), 3.74 (s, 3 H), 3.59 (dd, J ) 12.5, 8.0 Hz, 1 H), 3.40
(t, J ) 4.5 Hz, 1 H), 3.36 (s, 6 H), 2.84 (dd, J ) 12.5, 4.5 Hz, 1
H), 2.65 (dd, J ) 12.5, 4.5 Hz, 1 H), 2.39 (br, 1 H). 13C NMR (50
MHz, CDCl3) ä 173.1 (s), 103.5 (d), 62.7 (d), 62.5 (t), 53.9 (q),
53.1 (q), 52.0 (q), 49.1 (t). MS m/z 207 (M+, 26), 149 (13), 133
(18). Anal. Calcd for C8H17NO5: C, 46.37; H, 8.27; N, 6.76.
Found: C, 46.40; H, 8.31; N, 6.69.
(2S)-2-[(2,2-Dimethoxyethyl)(9H-fluoren-9-ylmethoxycarbo-
nyl)amino]-3-hydroxypropionic Acid Methyl Ester (4). To a
solution of 3 (1.14 g, 5.5 mmol) in 2:1 water-dioxane (15 mL)
was added NaHCO3 (0.92 g, 11.0 mmol), and the mixture was
cooled to 0 °C with an ice bath, then a solution of Fmoc-Cl (1.42
g, 5.5 mmol) in dioxane (15 mL) was added dropwise over 15 min.
The ice bath was removed, and the reaction mixture was left stirring
for 2.5 h. Successively, the mixture was partitioned between EtOAc
(40 mL) and water (20 mL), and the organic phase was washed
with 1 M HCl and brine and dried over Na2SO4. The organic
solvents were then removed under reduced pressure, and the crude
product was purified by flash column chromatography (EtOAc-
hexanes 3:2, Rf 0.53), thus giving pure 4 as a colorless oil (2.29 g,
97%). [R]22D -31.6 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3)
3:2 mixture of rotamers ä 7.76 (d, J ) 7.2 Hz, 2 H), 7.60 (d, J )
6.0 Hz, 1 H), 7.55-7.53 (m, 1 H), 7.42-7.39 (m, 2 H), 7.35-7.29
(m, 2 H), 4.76-4.69 (m, 2 H), 4.61-4.47 (m, 2 H), 4.24-4.21
(m, 1 H), 3.97-3.94 (m, 1 H), 3.86-3.80 (m, 1 H), 3.69 and 3.61
(s, 3 H), 3.69-3.59 (m, 1 H), 3.49 and 3.43 (2s, 2.4 H), 3.16 and
3.11 (2s, 3.6 H), 3.21-3.11 (m, 0.4 H), 2.97 (dd, J ) 15.2, 7.2
Hz, 0.6 H). 13C NMR (50 MHz, CDCl3) ä 170.0 (s), 156.6 (s),
143.4 (s, 2 C), 141.2 (s, 2 C), 127.6 (d, 2 C), 127.1 and 126.9 (d,
2 C), 124.6 and 124.5 (d, 2 C), 119.9 (d, 2 C), 103.3 and 103.0
(d), 67.7 and 66.6 (t), 62.9 and 62.1 (d), 60.7 and 60.2 (t), 55.6
(q), 54.7 (q), 52.2 (q), 49.1 and 48.9 (t), 47.3 and 47.0 (d). MS m/z
367 [0.2, M+ - (OCH3)2], 324 (0.2). Anal. Calcd for C23H27NO7:
C, 64.32; H, 6.34; N, 3.26. Found: C, 64.30; H, 6.39; N, 3.21.
(3S)-2,3-Dihydro[1,4]oxazine-3,4-dicarboxylic Acid 4-(9H-
Fluoren-9-ylmethyl) Ester 3-Methyl Ester (5). A solution of
compound 4 (1.1 g, 2.56 mmol) in toluene (25 mL) containing a
catalytic amount of p-toluenesulfonic acid monohydrate (49 mg,
0.26 mmol) was placed in a single-necked round-bottomed flask
equipped with a reflux condenser and dropping funnel containing
approximately 13 g of 4 Å molecular sieves. The mixture was
refluxed for 1.75 h. Then it was cooled to room temperature and
filtered through a thin layer of NaHCO3. Toluene was removed
under reduced pressure, and the crude product was purified by flash
column chromatography (hexanes-EtOAc 3:1, Rf 0.55) to yield
compound 5 as a white foam (795 mg, 85%). [R]23D +6.2 (c 1.0,
CH2Cl2). 1H NMR (400 MHz, CDCl3) 3:2 mixture of rotamers ä
7.77 (t, J ) 8.0 Hz, 1 H), 7.61 (t, J ) 8.0 Hz, 1 H), 7.50 (m, 1 H),
7.41 and 7.32 (m, 2 H), 6.42 (d, J ) 5.2 Hz, 0.4 H), 6.36 (d, J )
5.2 Hz, 0.6 H), 6.02 (d, J ) 5.2 Hz, 0.4 H), 5.98 (d, J ) 5.2 Hz,
0.6 H), 4.97 (s, 0.4 H), 4.68 (d, J ) 11.2 Hz, 0.4 H), 4.60-4.40
(m, 3.2 H), 4.32 (t, J ) 7.2 Hz, 0.6 H), 4.23 (t, J ) 7.2 Hz, 0.4 H),
3.99 (dd, J ) 11.2, 3.2 Hz, 0.6 H), 3.87 (dd, J ) 11.2, 3.2 Hz, 0.4
H), 3.86 (s, 1.8 H), 3.71 (s, 1.2 H). 13C NMR (50 MHz, CDCl3) ä
168.2 (s), 151.9 and 151.2 (s), 143.4 and 143.2 (s, 2 C), 141.0 (s,
2 C), 129.7 and 128.8 (d), 127.6 (d, 2 C), 126.9 (d, 2 C), 124.9
(d), 124.8 (d), 124.8 and 124.5 (d), 119.9 (d, 2 C), 105.9 and 105.3
(d), 68.3 and 67.8 (t), 65.4 and 64.9 (t), 54.5 and 53.9 (d), 52.8
(q), 47.0 and 46.9 (d). MS m/z 365 (M+, 7), 306 (0.4, M+ - CO2-
Me), 179 (100). Anal. Calcd for C21H19NO5: C, 69.03; H, 5.24;
N, 3.83. Found: C, 69.16; H, 5.31; N, 3.80.
(3S)-Morpholine-3,4-dicarboxylic Acid 4-(9H-Fluoren-9-yl-
methyl) Ester 3-Methyl Ester (6). Compound 5 (1.30 g, 3.3 mmol)
was dissolved in a 2:1 mixture of MeOH-CH2Cl2 (30 mL), and
10% Pt/C (166 mg) was added. The suspension was hydrogenated
overnight at room temperature, and then filtered over Celite. The
organic solvents were removed under reduced pressure and the
crude product was purified by flash column chromatography
(hexanes-EtOAc 2:1, Rf 0.48) to yield pure 6 as a white foam
(1.15 g, 95%). [R]24D -51.5 (c 1.0, CH2Cl2). 1H NMR (400 MHz,
CDCl3) mixture of rotamers ä 7.78-7.75 (t, J ) 6.9 Hz, 2 H),
7.60 (t, J ) 6.5 Hz, 1 H), 7.50 (t, J ) 7.1 Hz, 1 H), 7.43-7.38 (m,
2 H), 7.35-7.28 (m, 2 H), 4.65 (m, 0.5 H), 4.56-4.46 (m, 1.5 H),
4.44-4.37 (m, 1 H), 4.33-4.28 (m, 1.5 H), 4.24-4.20 (m, 0.5 H),
3.91-3.84 (m, 1.5 H), 3.78 and 3.73 (s, 3 H), 3.66 (dd, J ) 12.0,
2.4 Hz, 1.5 H), 3.58 (dd, J ) 12.0, 2.4 Hz, 0.5 H), 3.50-3.40 (m,
1.5 H), 3.22 (td, J ) 12.0, 4.0 Hz, 1 H). 13C NMR (50 MHz, CDCl3)
ä 169.9 (s), 143.7 and 143.5 (s, 2 C), 141.1 (s, 2 C), 127.5 (d, 2
C), 126.9 (d, 2 C), 124.8 (d), 124.6 and 124.5 (d), 119.8 (d, 2 C),
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67.8 and 67.5 (t), 67.5 and 67.2 (t), 66.5 and 66.1 (t), 54.6 and
54.3 (d), 52.5 (q), 47.0 (d), 41.5 and 41.0 (t). MS m/z 367 (M+,
0.6), 278 (0.8), 178 (9), 57 (100). Anal. Calcd for C21H21NO5: C,
68.65; H, 5.76; N, 3.81. Found: C, 68.70; H, 5.77; N, 3.82.
(3S)-Morpholine-3,4-dicarboxylic Acid 4-(9H-Fluoren-9-yl-
methyl) Ester [(S)-7]. Ester 6 (1.70 g, 4.6 mmol) was dissolved
in dioxane (12 mL) and 5 M HCl (12 mL) was added. The reaction
was refluxed for 18 h and then diluted with 5% Na2CO3 (120 mL).
The resulting solution was washed with diethyl ether and then the
aqueous layer was acidified to pH 1 with concentrated HCl and
the organic phase was extracted with CH2Cl2. The organic extracts
were combined, dried over Na2SO4, and concentrated under reduced
pressure to yield compound (S)-7 as a white solid (1.57 g, 97%).
Mp 128-130 °C. [R]24D -56.9 (c 1, CH2Cl2). 1H NMR (400 MHz,
CDCl3) mixture of rotamers ä 8.44 (br, 1 H), 7.69-7.62 (m, 2 H),
7.52-7.50 (m, 1 H), 7.44-7.39 (m, 1 H), 7.33-7.17 (m, 4 H),
4.62 (s, 0.5 H), 4.51-4.41 (m, 1.5 H), 4.38-4.32 (m, 1 H), 4.25-
4.11 (m, 2 H), 3.83-3.81 (m, 1 H), 3.71 (d, J ) 13.0 Hz, 0.5H),
3.65-3.50 (m, 1 H), 3.45 (dd, J ) 11.8, 3.8 Hz, 0.5 H), 3.42-
3.31 (m, 1.5 H), 3.22-3.16 (td, J ) 12.5, 3.4 Hz, 0.5 H). 13C NMR
(50 MHz, CDCl3) ä 173.7 and 173.5 (s), 156.1 and 155.5 (s), 143.5
and 143.3 (s, 2 C), 141.0 (s, 2 C), 127.5 (d, 2 C), 126.8 (d, 2 C),
124.7 (d), 124.5 and 124.4 (d), 119.7 (d, 2 C), 67.9 and
67.4 (t), 67.4 and 67.0 (t), 66.4 and 66.0 (t), 54.5 and 54.1 (d),
47.0 (d), 41.5 and 41.0 (t). ESI-MS m/z 354.09 (M+ + H, 8), 376.18
(M+ + Na, 100), 392.18 (M+ + K, 46). Anal. Calcd for C20H19-
NO5: C, 67.98; H, 5.42; N, 3.96. Found: C, 67.90; H, 5.43; N,
3.98.
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